SEHK:2157Biotechs
Lepu Biopharma (SEHK:2157): Valuation Check After Upfront Licensing Milestone with Excalipoint
Lepu Biopharma (SEHK:2157) just ticked off a key milestone, receiving its initial upfront licensing payment from Excalipoint after meeting deal conditions, a concrete step toward monetizing its CTM012 and CTM013 cancer assets.
See our latest analysis for Lepu Biopharma.
Despite today’s softer mood, with a negative 1 day share price return, Lepu Biopharma’s share price has still logged a triple digit year to date gain, while the 1 year total shareholder return, though strong, lags that surge...